This approach effectively reduces the false-negative rate of HER2 status in mucinous ovarian cancer, and the corresponding HER2-positive detection rate is effectively increased (Hodeib et al., 2015). This evidence concerns the gene ERBB2 and mucinous ovarian cancer.